WHO gives nod to Biological E as additional production site for JnJ COVID vaccine
India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.
New Delhi: Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine.
"Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing," the US embassy in India said in a tweet on Wednesday.
CORBEVAX is a protein sub-unit vaccine, developed from a component of the spike protein on the virus's surface, which helps the body build the immune response against the virus. The vaccine has the Receptor Binding Domain (RBD) protein as an antigen, CpG 1018 and Aluminium hydroxide as adjuvants formulated in Tris buffer.
Read also: DCGI nod to Biological E Corbevax as heterologous COVID booster
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.